Literature DB >> 16586444

Overview of the European and North American studies on HPV testing in primary cervical cancer screening.

Jack Cuzick1, Christine Clavel, Karl-Ulrich Petry, Chris J L M Meijer, Heike Hoyer, Samuel Ratnam, Anne Szarewski, Philippe Birembaut, Shalini Kulasingam, Peter Sasieni, Thomas Iftner.   

Abstract

Several studies suggest that HPV testing is more sensitive than cytology in primary cervical screening. These studies had different designs and were reported in different ways. Individual patient data were collected for all European and North American studies in which cytology was routinely performed and HPV testing was included as an additional parallel test. More than 60,000 women were included. The sensitivity and specificity of HPV testing were compared with routine cytology, both overall and for ages <35, 35-49 and 50+. The age-specific prevalence of high risk HPV (hr-HPV) was also analysed. HPV testing was substantially more sensitive in detecting CIN2+ than cytology (96.1% vs. 53.0%) but less specific (90.7% vs. 96.3%). The sensitivity of HPV testing was similar in all studies carried out in different areas of Europe and North America, whereas the sensitivity of cytology was highly variable. HPV sensitivity was uniformly high at all ages, whereas the sensitivity of cytology was substantially better in women over the age of 50 than in younger women (79.3% vs. 59.6%). The specificity of both tests increased with age. Positivity rates for HPV testing in women without high-grade CIN were region dependent. These results support the use of HPV testing as the sole primary screening test, with cytology reserved for women who test HPV positive. Large demonstration projects are needed to fully evaluate this strategy. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16586444     DOI: 10.1002/ijc.21955

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  266 in total

1.  Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer.

Authors:  Johannes Schweizer; Peter S Lu; Charles W Mahoney; Marthe Berard-Bergery; Minh Ho; Valli Ramasamy; Jon E Silver; Arnima Bisht; Yassine Labiad; Roger B Peck; Jeanette Lim; Jose Jeronimo; Roslyn Howard; Patti E Gravitt; Philip E Castle
Journal:  J Clin Microbiol       Date:  2010-10-06       Impact factor: 5.948

2.  Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice.

Authors:  Walter Kinney; Barbara Fetterman; J Thomas Cox; Thomas Lorey; Tracy Flanagan; Philip E Castle
Journal:  Gynecol Oncol       Date:  2011-01-26       Impact factor: 5.482

3.  Detection of human papillomavirus type 18 E7 oncoprotein in cervical smears: a feasibility study.

Authors:  Daniela Ehehalt; Barbara Lener; Haymo Pircher; Kerstin Dreier; Heiko Pfister; Andreas M Kaufmann; Sergio Frangini; Sigrun Ressler; Elisabeth Müller-Holzner; Markus Schmitt; Daniela Höfler; Ursula Rostek; Andreas Kaiser; Andreas Widschwendter; Werner Zwerschke; Pidder Jansen-Dürr
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

4.  Preventing cervical cancer globally by acting locally: if not now, when?

Authors:  Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2010-09-30       Impact factor: 13.506

Review 5.  A review of cancer in U.S. Hispanic populations.

Authors:  Robert W Haile; Esther M John; A Joan Levine; Victoria K Cortessis; Jennifer B Unger; Melissa Gonzales; Elad Ziv; Patricia Thompson; Donna Spruijt-Metz; Katherine L Tucker; Jonine L Bernstein; Thomas E Rohan; Gloria Y F Ho; Melissa L Bondy; Maria Elena Martinez; Linda Cook; Mariana C Stern; Marcia Cruz Correa; Jonelle Wright; Seth J Schwartz; Lourdes Baezconde-Garbanati; Victoria Blinder; Patricia Miranda; Richard Hayes; George Friedman-Jiménez; Kristine R Monroe; Christopher A Haiman; Brian E Henderson; Duncan C Thomas; Paolo Boffetta
Journal:  Cancer Prev Res (Phila)       Date:  2012-02

6.  Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China.

Authors:  Fang-Hui Zhao; Margaret Jane Lin; Feng Chen; Shang-Ying Hu; Rong Zhang; Jerome L Belinson; John W Sellors; Silvia Franceschi; You-Lin Qiao; Philip E Castle
Journal:  Lancet Oncol       Date:  2010-11-11       Impact factor: 41.316

7.  Human papillomavirus-related gynecologic neoplasms: screening and prevention.

Authors:  Whitfield B Growdon; Marcela Del Carmen
Journal:  Rev Obstet Gynecol       Date:  2008

8.  Squamous dysplasia of the rectum in a patient with ulcerative colitis treated with 6-mercaptopurine.

Authors:  Rachel Greenberg; Bruce Greenwald; J Scott Roth; Olga Ioffe; Raymond Cross
Journal:  Dig Dis Sci       Date:  2007-08-24       Impact factor: 3.199

9.  Quantitative DNA methylation analysis of paired box gene 1 and LIM homeobox transcription factor 1 α genes in cervical cancer.

Authors:  Ling Xu; Jun Xu; Zheng Hu; Baohua Yang; Lifeng Wang; Xiao Lin; Ziyin Xia; Zhiling Zhang; Yunheng Zhu
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

10.  Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study.

Authors:  Philip E Castle; Patti E Gravitt; Diane Solomon; Cosette M Wheeler; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.